The company stems from the groundbreaking research carried out by Prof. Mauro Giacca, currently Professor of Cardiovascular Sciences and Head of the School of Cardiovascular and Metabolic Medicine & Sciences, King’s College London.
Millions of patients in the world suffer a myocardial infarction every year, with ischemic heart disease still being one of the leading causes of death worldwide. Heqet Therapeutics is advancing its pipeline of first-in-class compounds for cardiac regeneration to address this large unmet clinical need.